Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

UBS lowered the firm’s price target on Incyte (INCY) to $61 from $69 and keeps a Neutral rating on the shares. The stock has held up since the ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

WILMINGTON, Del., April 07, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 20,334 shares of the ...